A Study to Evaluate the Efficacy and Safety of AD-209

Addpharma

Status and phase: Completed; Phase 2

Conditions: Hypertension, Essential

Treatments: Drug: AD-209 placebo; Drug: AD-209-1B; Drug: AD-209-1 placebo; Drug: AD-209; Drug: AD-209-1C; Drug: AD-209-1A

Study type: Interventional

Funder types: Industry

Identifiers

NCT05631990

AD-209P2-02

Details and patient eligibility

About

The purpose of this study is to evaluate the efficacy and safety of AD-209

Full description

Condition or disease : hypertension Intervention/treatment Drug : AD-209 Drug : AD-209-1A Drug : AD-209-1B Drug : AD-209-1C Drug : AD-209 Placebo Drug : AD-209-1 Placebo Phase : Phase 2

Enrollment: 221 patients

Sex: All

Ages: 19 to 74 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Signed informed consent
• Other inclusions applied

Exclusion criteria

• orthostatic hypotension with symptom
• Other exclusions applied

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

221 participants in 4 patient groups

Experimental 1

Experimental group

Description:

AD-209, AD-209-1 placebo

Treatment:

Drug: AD-209

Drug: AD-209-1 placebo

Experimental 2

Experimental group

Description:

AD-209-1A, AD-209 placebo

Treatment:

Drug: AD-209 placebo

Drug: AD-209-1A

Experimental 3

Experimental group

Description:

AD-209-1B, AD-209 placebo

Treatment:

Drug: AD-209 placebo

Drug: AD-209-1B

Experimental 4

Experimental group

Description:

AD-209-1C, AD-209 placebo

Treatment:

Drug: AD-209 placebo

Drug: AD-209-1C